ArticleFrontiers in medicine2025
Efficacy of YL-1 hematoma crushing needle combined with hematoma drainage in intracerebral hemorrhage treatment.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Study on the Expression of MiR-642b-3p in Spontaneous Intracerebral Hemorrhage and Its Regulatory Mechanism on Endothelial Cell Injury.Neurochemical research · 2026Article
- Clinical benefit of robot-assisted minimally invasive stereotactic aspiration/drainage in hypertensive intracerebral hemorrhage.American journal of translational research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Early craniotomy evacuation in hematoma surgery does not significantly improve the prognosis of patients with spontaneous intracerebral hemorrhage (ICH). The YL-1 hematoma crushing puncture needle, specifically designed for ICH evacuation, has an uncertain therapeutic efficacy. This study aimed to evaluate its clinical effectiveness. Materials and methods: We retrospectively reviewed medical records of patients with ICH who underwent twist intraosseous drill needle (TIDN) surgery at our institution between September 2016 and March 2023. Clinical outcomes were analyzed. Results: The surgical group demonstrated a significantly shorter hematoma resolution time, averaging 14.71 days less than the conservative group ( Conclusion: TIDN surgery combined with hematoma drainage may serve as a viable surgical alternative for basal ganglia hemorrhage patients. This approach appears to reduce mannitol usage, mitigate craniotomy-associated risks, and promote short-term improvements in GCS scores and Barthel Index, highlighting its potential clinical benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.